STRATA Skin Sciences Inc announces the publication of an independent study on the treatment of vitiligo using the Company’s XTRAC excimer laser.

The study was conducted by a team of dermatologists in Japan and was approved by the Ethics Committee of Kansai Medical University Kori Hospital. The results of the study were published recently in the Journal of The European Academy of Dermatology and Venereology.

The study results demonstrated that patients with refractory vitiligo achieved satisfactory repigmentation in five treatments, including those who were previously unresponsive to conventional treatments such as topical steroids, excimer light and narrowband UVB light. These patients were treated under a minimal blistering dose protocol using the XTRAC excimer laser.

The study attributed better patient outcomes to XTRAC’s higher irradiation rate. In addition, the XTRAC treatments were well tolerated, and the use of a minimal blistering dose was shown to potentially reduce the number of treatment sessions required, thereby lessening the burden on patients and medical staff, a media release from SRATA Skin Sciences explains.

“We are delighted to see independent studies performed that continue to validate and highlight the efficacy of our XTRAC excimer laser in treating dermatologic diseases. There is a large unmet need in Japan for the treatment of vitiligo, a devastating condition with limited treatment options.

As we continue our focus on delivering our therapy solution to patients in Japan, we are encouraged by the positive results of this study to support our efforts; the data clearly demonstrate improved clinical outcomes with XTRAC treatments over the alternatives to treat vitiligo.”

— Bob Moccia, President and Chief Executive Officer

[Source(s): STRATA Skin Sciences Inc, GlobeNewswire]

Related Content:
Can Stress Trigger or Exacerbate Vitiligo?
Clinical Study Aims to Evaluate Vitiligo Repigmentation System
Long-Term Phototherapy for Vitiligo Associated With Reduced Risk for Heart Disease, Stroke